Quarterly ResultAug 5, 2026, 04:22 PM
Caris Life Sciences Q2 Revenue $263.7M, Raises 2026 Guidance
AI Summary
Caris Life Sciences reported strong financial results for the second quarter of 2026, with total revenue increasing 45% year-over-year to $263.7 million and a significant reduction in net loss to $0.6 million. The company achieved positive Adjusted EBITDA of $55.7 million and positive free cash flow of $6.4 million. Following this performance, Caris Life Sciences raised its full-year 2026 revenue guidance to a range of $1.03 billion to $1.04 billion, reflecting continued growth and operational improvements. Additionally, the company launched several new products, including Caris Detect, and announced a share repurchase program.
Key Highlights
- Total revenue for Q2 2026 was $263.7 million, a 45% increase year-over-year.
- Reported a net loss of $0.6 million, significantly improved from $71.8 million loss year-over-year.
- Achieved positive Adjusted EBITDA of $55.7 million.
- Generated positive free cash flow of $6.4 million.
- Increased 2026 revenue guidance to $1.03 billion to $1.04 billion, representing 27-28% growth.
- Launched Caris Detect, a multi-cancer early detection blood test.
- Announced a share repurchase program of up to $100 million, with $82.1 million remaining.
Price Impact
More from CAI